Typically, we give space to the Publishers’ Commentary in the December issue, in which Publisher Bruce Poorman and Associate Publisher Laurence Doyle take a look back at the year and toward the one to come. And then, in January, I come along with an Editor’s Focus column talking about editorial changes and tweaks and the like for the new year.
We thought we’d streamline things a bit and handle both at once so we can get right back into more market/industry-oriented fare on this page right out the starting gate in 2016.
So, without further ado...
From the chief editor
We saw a lot of nice, thick issues this year, a testament not only to advertiser support but also reader interest and a plethora of news to cover. The magazine will look much the same, but here are some recent and upcoming changes to address:
- We will continue to offer seven news sections spanning the pharma/biotech pipeline stages, having debuted Contract Services just a few issues ago. The new section isn’t going anywhere, as the importance and influence of CROs, CMOs and CDMOs certainly isn’t any time in the forseeable future.
- As we’ve mentioned before, the Q&A page that has appeared for a while now in the back of the magazine will continue to be a monthly affair, but will usually appear only on our website. Don’t worry—we’ll give you directions to its online home in the Business & Government Policy section when it doesn’t run physically.
- The Finance page and Markets page in the front of the magazine are getting an overhaul. Both pages will now be called Market News and will take a step back from talk about financing rounds and public company news to focus more on news of market trends and the like.
- Finally, we’ll be adding a new page to the end of the magazine called Late-breaking News. It’s a page we’ve run from time to time, but we’re now giving it a regular spot. Good news for you readers who start from the back, as you’ll start off seeing one or two items that occurred too late to assign a reporter to cover but are too important or interesting not to cover.
From the publishers
This has been a wonderful year for us on the DDNews team. Readers and advertisers alike seem to be getting even more out of the magazine and our web vehicles this year, and we are excited to see what the new year will bring. And as a side note, this is our first full year with the new paper stock we adopted in late 2014, and we think those of you who still like to hold a magazine in your hands will agree it’s made everything a greater joy to behold and an easier read.
We wanted to take a moment to let you know what’s on tap for Special Reports in the 2016 issues of DDNews, starting with a January 2016 Special Report on Regenerative Medicine that will examine current efforts in regenerative ophthalmology, where researchers are applying stem cell technologies to understand and treat diseases such as age-related macular degeneration and retinitis pigmentosa.
And for the rest of the year:
- The April issue focus will be Neuroscience
- The June issue focus will be Cancer
- The July issue focus will be Cell Biology
- The August issue focus will be Stem Cells
- The October issue focus will be Drug Metabolism
- The December issue focus will be Biotherapeutics
As for the specific angles each Special Report will take, it’s too early to say, but if you’re a company or expert in one of those market spaces and want to see if there’s room to share your thoughts in one of them, contact Features Editor Randall Willis at firstname.lastname@example.org.
We thank you for your readership, and we continue to look forward to giving you not just the news you might have heard vaguely about around work or elsewhere, but also the news you didn’t even know you needed to know.